


PHARMACEUTICAL 2018

Regulus Therapeutics Inc. Rank 258 of 342









Regulus Therapeutics Inc. Rank 258 of 342



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -19%, being 64% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	66,736
Cost of Goods Sold	0
Intangible Assets	775
Liabilities, Current	32,600
Liabilities, Non-Current	0
Other Assets	590
Other Compr. Net Income	-11
Other Expenses	2,526
Other Liabilities	9,993
Other Net Income	0
Other Revenues	824
Property and Equipment	9,708
Research and Development	53,192
Selling, General and Administrative Expense	17,011

Output Variable	Value in 1000 USD
Assets	77,809
Liabilities	42,593
Expenses	72,729
Revenues	824
Stockholders Equity	35,216
Net Income	-71,905
Comprehensive Net Income	-71,910
Economic Capital Ratio	-19%

